Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas

Diabetologia

Volumn 42, Issue 3, 1999, Pages 263-285

  Mogensen, C E ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Angiotensin converting enzyme inhibition; Antihypertensive treatment; Blood pressure; Dextran clearance; Diabetic nephropathy; Exercise; Glycaemic control; Hyperfiltration; Hyperglycaemia; Hypertension; Meta analysis; Metabolic syndrome; Microalbuminuria; Proteinuria; Risk factors for nephropathy; Type I diabetes; Type II diabetes

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DEXTRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; DIABETIC NEPHROPATHY; GENETICS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY HYPERTROPHY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; ULTRAFILTRATION;

EID: 0032989007     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051151     Document Type: Review

References (321)

1. 1. Mogensen CE (1989) Hyperfiltration, hypertension, and diabetic nephropathy in IDDM patients. Based on the Golgi Lecture 1988, EASD meeting, Paris. Diabetes Nutrition & Metabolism 2: 227-244
2. 2. Mogensen CE, Christensen CK, Vittinghus E (1983) The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32: 64-78
3. 3. Mogensen CE, Chachati A, Christensen CK et al. (1985-6) Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Investigation 9: 85-95
4. 4. Mogensen CE (1987) Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31: 673-689
5. 5. Mogensen CE (1990) Prediction of Clinical Diabetic Nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes 37: 761-767
6. 6. Mogensen CE, Marshall SM (1990) Early diagnosis of diabetic nephropathy. Twelve assertions on microalbuminuria and early nephropathy. In: Andreucci et al. (eds) International Yearbook of nephrology. Kluwer Academic Publ., Boston, Dordrecht, London pp 123-146
7. 7. Mogensen CE, Hansen KW, Klebe J et al. (1991) Microalbuminuria: Studies in diabetes, essential hypertension, and renal diseases as compared with the background population. In: Grünfeld JP (ed) Advances in Nephrology, vol. 20. Mosby Year Book, Chicago, Illinois, pp 191-228
8. 8. Mogensen CE, Hansen KW, Østerby R, Damsgaard EM (1992) Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes. Diabetes Care 15: 1192-1204
9. 9. Mogensen CE, Damsgaard EM, Frøland A (1992) GFR-loss and cardiovascular damage in diabetes: A key role for abnormal albuminuria. Acta Diabetol 29: 201-213
10. 10. Mogensen CE, Damsgaard EM, Frøland A, Nielsen S, de Fine Olivarius N, Schmitz A (1992) Microalbuminuria in non-insulin-dependent diabetes. Clin Nephrol [Suppl 1]38:S28-S39
11. 11. Mogensen CE, Christensen CK, Christensen PD (1993) The abnormal albuminuria syndrome in diabetes. Microalbuminuria: Key to the complications. In: Belfiore F, Bergman RN, Molinatti GM (eds) Current Topics in Diabetes Research. Front Diabetes. Karger, Basel, pp 86-121
12. 12. Mogensen CE, Poulsen PL, Heinsvig EM (1993) Abnormal albuminuria in the monitoring of early renal changes in diabetes. In: Mogensen CE, Standl E (eds) Concepts for the Ideal Diabetes Clinic. Diabetes Forum Series, Volume IV. Walter de Gruyter, Berlin, New York, pp 289-313
13. 13. Mogensen CE (1999) Diabetic nephopathy: Natural history and management. In: Ei Nahas (ed) Mechanisms and clinical management of progressive renal failure. Oxford University Press, Oxford, in press
14. 14. Mogensen CE (1998) Definition of diabetic renal disease in insulin-dependent diabetes mellitus based on renal function tests. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ, Boston, Dordrecht, London, pp 17-30
15. 15. Parving H-H (1998) Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 41: 745-759
16. 16. Parving H-H, Jensen HÆ, Mogensen CE, Evrin PE (1974) Increased urinary albumin excretion rate in benign essential hypertension. Lancet I: 1190-1192
17. 17. Bianchi S, Bigazzi R, Campese VM (1998) Microalbuminuria in patient with essential hypertension. Cardiovascular and renal implications. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ, Boston, Dordrecht, London, pp 569-584
18. 18. Christensen CK, Krussel LR, Mogensen CE (1987) Increased blood pressure in diabetes: Essential hypertension or diabetic nephropathy? Scand J Clin Lab Invest 47: 363-370
19. 19. Pedersen EB, Mogensen CE (1976) Effect of antihypertensive treatment on urinary albumin excretion, glomerular filtration rate and renal plasma flow in patients with essential hypertension. Scand J Clin Lab Invest 36: 231-237
20. 20. Damsgaard EM, Mogensen CE (1986) Microalbuminuria in elderly hyperglycaemic patients and controls. Diabetic Medicine 3: 430-435
21. 21. Damsgaard EM, Frøland A, Mogensen CE (1988) Albumin excretion above 15 μg/min is a strong predictor of death in elderly diabetics and non-diabetics. Diabetes Res Clin Pract 5 [Suppl 1]:S9 (Abstract)
22. 22. Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE (1993) Prognostic value of urinary albumin excretion rate and other risk factors in elderly diabetic patients and non-diabetic control subjects surviving the first 5 years after assessment. Diabetologia 36: 1030-1036
23. 23. Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE (1990) Microalbuminuria as predictor of increased mortality in elderly people. BMJ 300: 297-300
24. 24. Vestbo E, Damsgaard EG, Mogensen CE (1997) The relationship between microalbuminuria in first generation diabetic and non-diabetic subjects and microalbuminuria and hypertension in the second generation (a population based study). Nephrol Dial Transplant 12 [Suppl 2]: 32-36
25. 25. Vestbo E, Damsgaard EM, Frøland A, Mogensen CE (1996) Birth weight and cardiovascular risk factors in an epidemiological study. Diabetologia 39: 1598-1602
26. 26. Vestbo E, Damsgaard EM, Frøland A, Mogensen CE (1995) Urinary albumin excretion in a population based cohort. Diabet Med 12: 488-493
27. 27. Yudkin JS, Forrest RD, Jackson CA (1988) Microalbumuminuria as predictor of vascular disease in non-diabetic subjects. Lancet ii:530-533
28. 28. Feldt-Rasmussen B, Jensen JS, Borch-Johnsen K (1998) Value of screening for microalbuminuria in people with diabetes as well as in the general population. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ, Boston, Dordrecht, London, pp 151-162
29. 29. Olivarius de FN, Andreasen AH, Keiding N, Mogensen CE (1993) Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes care in General Practice", Denmark. Diabetologia 36: 1007-1016
30. 30. Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA (1998) Microalbuminria is strongly associated with NIDDM and hypertension but not with the insulin resistance syndrome: the Hoorn Study. Diabetologia 41: 694-700
31. 31. Mogensen CE, Klebe JG (1998) Microalbuminuria and diabetic pregnancy. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus, 4th edn., Kluwer Academic Publ., Boston, Dordrecht, London, pp 455-462
32. 32. Ferrannini E (1993) The metabolic syndrome. In: Morgensen CE (ed) Target organ damage in the mature hypertensive. Science Press, London, pp 2.31-2.49
33. 33. Mogensen CE, Hansen KW, Mau Pedersen M, Christensen CK (1991) Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 14: 13-26
34. 34. Mogensen CE, Mau Pedersen M, Hansen KW, Christensen CK (1992) Micro-albuminuria and the organ-damage concept in antihypertensive therapy for patients with insulin-dependent diabetes mellitus. Journal of Hypertension 10:S43-S51
35. 35. Mogensen CE (1995) Diabetic Renal Disease: The Quest for Normotension - and Beyond. Diabetic Medicine 12: 756-769
36. 36. Mogensen CE (1995) Management of the diabetic patient with elevated blood pressure or renal disease. Early screening and treatment programs. In: Laragh JH, Brenner BM (eds) Albuminuria and Blood Pressure. Hypertension: Pathophysiology, Diagnosis, and management. 2nd ed., Raven Press Ltd. N. Y., pp 2335-2365
37. 37. Mogensen CE (1990) Prevention and treatment of renal disease in insulin-dependent diabetes mellitus. Semin Nephrol 10: 260-273
38. 38. Mogensen CE (1994) Renoprotective role of ACE inhibitors in diabetic nephropathy. Brit Heart J 72 (1):38-45
39. 39. Mogensen CE (1994) Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J Intern Med 235: 297-316
40. 40. Ohkubo Y, Kishikawa H, Araki E et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research Clinical Practice 28: 103-117
41. 41. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329: 977-986
42. 42. Østerby R, Hansen R (1965) A quantitative estimate of the peripheral glomerular basement membrane in recent juvenile diabetes. Diabetologia 1: 97-100
43. 43. Østerby R (1971) Course of Diabetic Glomerulopathy. Acta Diabet Latina 8 (1):179-191
44. 44. Østerby R (1972) Morphometric studies of the peripheral glomerular basement membrane in early juvenile diabetes. I. Development of initial basement membrane thickening. Diabetologia 8: 84-92
45. 45. Berg UB, Torbjörnsdotter TB, Jarenko G, Thalme B (1998) Kidney morphological changes in relation to long-term renal function and metabolic control in adolescents with IDDM. Diabetologia 41: 1047-1056
46. 46. Østerby R (1990) Basement membrane morphology in diabetes mellitus. In: Ellenberg & Rifkin's Diabetes Mellitus, theory and practice, 4th ed., Elsevier, N. Y., Amsterdam, London, pp 220-233
47. 47. Østerby R (1996) Lessons from kidney biopsies. Diabetes Metabol Rev 12: 151-174
48. 48. Bangsted HJ, Østerby R, Dahl-Jørgensen K, Berg KJ, Hartmann A, Hanssen KF (1994) Improvement of blood glucose control retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37: 483-490
49. 49. Williamson JR, Vogler NJ, Kilo C (1971) Structural abnormalities in muscle capillary basement membrane in diabetes mellitus. Acta Diabet Latina 8 [Suppl 1]:117-134
50. 50. Mau Pedersen M, Christensen SE, Christiansen JS, Pedersen EB, Mogensen CE, Ørskov H (1990) Acute effects of the somatostatin analogue on kidney function in Type 1 diabetic patients. Diabetic Med 7: 304-309
51. 51. Mau Pedersen M, Christiansen JS, Mogensen CE (1991) Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 months of aldose reductase inhibition. Diabetes 40: 527-531
52. 52. Mau Pedersen M, Mogensen CE, Christiansen JS (1995) Reduction of glomerular hyperfunction during short-term aldose reductase inhibition in normoalbuminuric, insulin-dependent diabetic patients. Endocrinology and Metabolism 2: 55-56
53. 53. Mau Pedersen M, Mogensen CE, Schønau Jørgensen F, Møller B, Lykke G, Pedersen O (1989) Renal effects of limitation of high dietary protein in normoalbuminuric insulin-dependent diabetic patients. Kidney Int 36 [Suppl 27]:S115-S121
54. 54. Mau Pedersen M, Winther E, Mogensen CE (1990) Reducing protein in the diabetic diet. Diabetes Metab 16: 454-459
55. 55. Mogensen CE (1986) Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 46: 201-206
56. 56. Mogensen CE (1994) Glomerular hyperfiltration in human diabetes. Diabetes Care 17: 770-775
57. 57. Mogensen CE, Sølling K, Vittinghus E (1981) Studies on mechanisms of proteinuria using aminoacid-induced inhibition of tubular reabsorption in normal and diabetic man. Contr Nephrol 26: 50-65
58. 58. Mogensen CE, Christensen CK, Christensen NJ, Gundersen HJG, Jacobsen FK, Pedersen EB, Vittinghus E (1981) Renal protein handling in normal, hypertensive and diabetic man. Contr Nephrol 24: 139-152
59. 59. Turner RC, Millns H et al. for the United Kingdom Prospective Diabetes Study Group (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). British Medical Journal 316: 823-828
60. 60. Mogensen CE, Vigstrup J, Ehlers N (1985) Microalbuminuria predicts proliferative diabetic retinopathy. Lancet II:1512-1513
61. 61. Gilbert RE, Tsalamandris C, Allen TJ, Colville D, Jerums G (1998) Early nephropathy predicts vision-threatening retinal disease in patients with type 1 diabetes mellitus. Journal of the American Society of Nephrology 9: 85-89
62. 62. Bernard C (1849) Compte Rendu de la Société du Biologie. Paris. Vol. 1: 80-81
63. 63. Deckert D (1998) Historical aspects of diabetes and diabetic renal disease. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus. 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London pp 1-6
64. 64. Rayer P (1839) Traité des maladies des Reins et des altérations de la sécrétion urinaire, etudiées en elles-mémes et dans leurs rapports avec les maladies des uretéres, de la vessie, de la prostate, de l'urèthre, etc. Libraire de l'Académie Royale de médicine, Paris
65. 65. Rayer P (1841) Traité des maladies des Reins et des altérations de la sécrétion urinaire, etudiées en elles-mémes et dans leurs rapports avec les maladies des uretéres, de la vessie, de la prostate, de l'urèthre, etc. Libraire de l'Académie Royale de médicine, Paris
66. 66. Ross J, Goldmann JK (1971) Effect of streptozotocin-induced diabetes on kidney weight and compensatory hypertrophy in the rat. Endocrinology. 88: 1079-1082
67. 67. Mogensen CE, Andersen MJF (1973) Increased kidney size and glomerular filtration rate in early juvenile diabetes. Diabetes 22: 706-712
68. 68. Mogensen CE, Andersen MJF (1975) Increased kidney size and glomerular filtration rate in untreated juvenile diabetics. Normalization by insulin treatment. Diabetologia 11: 221-224
69. 69. Baumgartl HJ, Banholzer P, Sigl G, Haslbeck M, Standl E (1998) On the prognosis of IDDM patients with large kidneys. The role of large kidneys for the development of diabetic nephropathy. Nephrol Dial Transplant 13: 630-634
70. 70. Hostetter TH, Rennke HG, Brenner BM (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72: 375-380
71. 71. Rudberg S, Persson B, Dahlquist G (1992) Increased glomerular filtration rate as a predictor of diabetic nephropathy - An 8-year prospective study. Kidney Int 41: 822-828
72. 72. Mogensen CE (1971) Kidney function and glomerular permeability in early juvenile diabetes. Scand J Clin Lab Invest 28: 79-90
73. 73. Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 89-93
74. 74. Mau Pedersen M, Christiansen JS, Pedersen EB, Mogensen CE (1992) Determinants of intra-individual variation in kidney function in normoalbuminuric insulin-dependent diabetic patients: importance of atrial natriuretic peptide and glycaemic control. Clinical Science 83: 445-451
75. 2 microglobulin in essential hypertension induced by atrial natriuretic peptide. Scand J Clin Lab Invest 51: 359-366
76. 76. Lutterman JA, Vervoort G, Wetzels JFM, Berden JHM, Smits P (1998) Increased albuminuric response to infusion of atrial natriuretic peptide in normoalbuminuric Type I diabetes. Diabetologia 41:A39
77. 77. Mau Pedersern M (1998) Early renal hyperfunction and hypertrophy in IDDM patients including comments on early intervention. In: Mogensen CE (ed) The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publ., Boston, Dordrecht, London, pp 383-392
78. 78. Østerby R, Gall M-A, Schmitz A, Nielsen FS, Nyberg G, Parving H-H (1993) Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 1064-1070
79. 79. Mogensen CE (1998) Combined high blood pressure and glucose in type 2 diabetes: double jeopardy (editorial). BMJ 317: 693-694
80. 80. American Diabetes Association (1999) Implications of the United Kingdom Prospective Diabetes study Diabetes Care 22, Suppl. 1 S27-S31
81. 81. Borch-Johnsen K, Nissen H, Henriksen E, Kreiner S, Salling N, Deckert T, Nerup J (1987) The natural history of insulin-dependent diabetes mellitus in Denmark: 1. Long-term survival with and without late diabetic complications. Diabet Med 4: 201-210
82. 82. Siperstein MD, Unger RH, Madison LL (1968) Studies of muscle Capillary Basement Membranes in Normal Subjects, Diabetic and Prediabetic Patients. J Clin Invest 47: 1973-1999
83. 83. Deckert T, Poulsen JE (1981) Diabetic nephropathy: fault or destiny? Diabetologia 21: 178-183
84. 84. Pirart J (1978) Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1: 168-188
85. 85. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T (1991) Effect of improved metabolic control loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34: 164-170
86. 86. Tarnow L, Gluud C, Parving H-H (1998) Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrology Dialysis Transplantation 13: 410-412
87. 87. Alaveras EAG, Thomas SM, Sagriotis A, Viberti GC (1997) Promotors of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrology Dialysis Transplantation 12: 71-74
88. 88. Björck S, Blohmé G, Sylvén C, Mulec H (1997) Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrology Dialysis Transplantation 12: 67-70
89. 89. Fagerudd JA, Tarnow L, Jacobsen P et al. (1998) Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 47: 439-444
90. 90. Rudberg S, Stattin E-L, Dahlquist G (1998) Familial and perinatal risk factors for micro-and macroalbuminuria in young IDDM patients. Diabetes 47: 1121-1126
91. 91. Cowie CC, Port F, Wolfe R, Savage PJ, Moll PP, Hawthorne VM (1989) Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 321: 1074-1079
92. 92. Freedman BI, Soucie JM, McClellan WM (1997) Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 8:1942-1945
93. 93. Borch-Johnsen K, Nørgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving H-H (1992) Is diabetic nephropathy an inherited complication? Kidney Int 41: 719-722
94. 94. Barker DJP (1994) Mothers, babies and diseases in later life. BMJ Publishing Group
95. 95. Nyengaard JR, Bendtsen TF, Mogensen CE (1996) Low birth weight - is it associated with few and small glomeruli in normal persons and NIDDM (non-insulin-dependent diabetes mellitus) patients? Diabetologia 39: 1634-1637
96. 96. Nyengaard JR, Vestbo E (1998) The concept of low birth weight and renal disease. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 123-130
97. 97. Ravelli ACJ, van der Meulen JHP, Michels RPJ, Osmond C, Barker DJP, Hales CN, Bleker OP (1998) Glucose tolerance in adults after prenatal exposure to famine. Lancet 351: 173-177
98. 98. Yudkin JS, Stanner S (1998) Prenatal exposure to famine and health in later life. Lancet 351: 1361-1362
99. 99. Berggård I, Risinger G (1961) Quantitative immunochemical determination of albumin in normal human urine. Acta Soc Med Upsaliensis 66: 217-222
100. 100. Keen H, Chlouverakis C, Fuller J, Jarret RS (1969) The concomitants of raised blood sugar: studies in newly-detected hyperglycaemics. II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. Guy's Hospital Reports 118: 247-254
101. 101. Bigazzi R, Bianchi S, Baldari D, Campese VM (1998) Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16: 1325-1333
102. 102. Poulsen PL, Mogensen CE (1995) Evaluation of a new semiquantitative stix for microalbuminuria. Diabetes Care 18: 732-733
103. 103. Mogensen CE, Viberti GC, Peheim E et al. (1997) Multi-center evaluation of the Micral-test II test strip, an immunologic rapid test for the detection of microalbuminuria. Diabetes Care 20: 1642-1646
104. 104. Poulsen PL, Mogensen CE (1998) Clinical evaluation of a test for immediate and quantitative determination of urinary albumin-to-creatinine ratio. Diabetes Care 21: 97-98
105. 105. Parving H-H, Oxenbøll B, Svendsen PA, Christiansen JS, Andersen AR (1982) Early detection of patients at risk of developing diabetic nephropathy. A prospective study of urinary albumin excretion. Acta Endocrinol (Copenhagen) 100: 550-555
106. 106. Viberti GC, Hill RD, Jarret RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet I:1430-1432
107. 107. Mau Pedersen M, Christensen CK and Mogensen CE (1992) Long-term (18 year) prognosis for normo- and microalbuminuric type 1 (insulin-dependent) diabetic patients. Diabetologia 35:A60 (Abstract)
108. 108. Messent JWC, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC (1992) Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three year follow-up study. Kidney International 41: 836-839
109. 109. Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H (1996) Risk factors for mortality in IDDM patients, a 10 years observational follow up study. BMJ 313: 779-784
110. 110. Forsblom CM, Groop P-H, Ekstrand A, Groop LC (1992) Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 305: 1051-1053
111. 111. Mogensen CE (1983) Microalbuminuria in maturity onset, primarily type 2 (non-insulin-dependent) diabetes, predicts clinical proteinuria and early mortality. Diabetologia 26: 181 (Abstract)
112. 112. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310: 356-360
113. 113. Dinneen S, Gerstein HC (1997) The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157: 1413-1418
114. 114. Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R (1998) Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM Patients. Diabetes Care 21: 116-120
115. 115. Forsblom CM, Groop P-H, Ekstrand A et al. (1998) Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 21: 1932-1938
116. 116. Schmitz A (1997) Microalbuminuria, blood pressure, metabolic control, and renal involvement. Longitudinal studies in white non-insulin-dependent diabetic patients. American Journal of Hypertension 10: 189S-197S
117. 117. Schmitz A, Væth M, Mogensen CE (1994) Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 37: 1251-1258
118. 118. Nielsen S, Schmitz O, Ørskov H, Mogensen CE (1995) Similar insulin sensitivity in NIDDM patients with normo-and microalbuminuria. Diabetes Care 18: 834-842
119. 119. Nielsen S, Schmitz O, Møller N, Pørksen N, Klausen IC, Alberti KGMM, Mogensen CE (1993) Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36: 1079-1086
120. 120. Nielsen S, Schmitz A, Rehling M, Mogensen CE (1997) The clinical course of renal function in NIDDM patients with normo- and microalbuminuria. J Intern Med 241: 133-141
121. 121. Nielsen S, Schmitz A, Rehling M, Mogensen CE (1993) Systolic blood pressure determines the rate of decline of glomerular filtration rate in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetes Care 16: 1427-1432
122. 122. Nielsen S, Schmitz A, Poulsen PL, Hansen KW, Mogensen CE (1995) Albuminuria and 24-h ambulatory blood pressure in normoalbuminuric and microalbuminuric NIDDM patients: a longitudinal study. Diabetes Care 18: 1434-1441
123. 123. Nielsen S, Schmitz A, Derkx FHM, Mogensen CE (1995) Prorenin and renal function in NIDDM patients with normo- and microalbuminuria. J Intern Med 238: 499-505
124. 124. Nielsen S, Schmitz A, Bacher T, Rehling M, Ingerslev J, Mogensen CE (1999) Effects of short-term treatment with low-molecular weight heparin in NIDDM patients with and without abnormal albuminuria. Dissociation of albuminuria and transcapillary escape rate of albumin as markers of microvascular dysfuntion. Diabetologia (in press)
125. 125. Nielsen S, Schmitz A, Knudsen RE, Dollerup J, Mogensen CE (1994) Enalapril versus bendroflumethiazide in type 2 diabetes complicated by hypertension. Q J Med 87: 747-754
126. 126. Fioretto P, Stehouwer CDA, Mauer M et al. (1998) Heterogeneous nature of microalbuminuria in NIDDM: Studies of endothelial function and renal structure. Diabetologia 41: 233-236
127. 127. Inomata S, Osawa Y, Itoh M (1987) Analysis of urinary proteins in diabetes mellitus - with reference to the relationship between microalbuminuria and diabetic renal lesions. J Jpn Diabetes Soc 30: 429-436
128. 128. UKPDS 33 (1998) An intensive blood glucose control policy with sulphonylureas or insulin reduces the risk of diabetic complications in patients with Type 2 diabetes. Lancet 352: 837-853
129. 129. UKPDS 34 (1998) Effect of an intensive blood glucose control policy with metformin on complications in Type 2 diabetic patients. Lancet 352: 854-865
130. 130. Turner R, Holman R, Stratton I et al. for United Kingdom Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom prospective diabetes study 38. BMJ 317: 703-713
131. 131. Holman R, Turner R, Stratton I et al. for United Kingdom Prospective Diabetes Study Group (1998). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: United Kingdom prospective diabetes study 39. BMJ 317: 713-720
132. 132. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco RG, Strollo G, Strollo F (1998) Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trials (FACET) in patients with hypertension and NIDDM. Diabetes Care 21: 597-603
133. 133. Tuomilehto J, Rastenyte D, Thisj L, Staessen J (1998) Reduction of mortality and cardiovascular events in older diabetic patients with isolated systolic hypertension in Europe treated with nitrendipine-based antihypertensive therapy (Syst-Eur-Trial). Diabetes 47:A54 (Abstract)
134. 134. Hansson L, Zanchetti A, Carruthers SG et al. for the HOT Study Group (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755-1762
135. 135. Estacio RO, Jeffers BW, Hiatt RA, Biggerstaff SL, Gifford N, Schrier RW (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338: 645-652
136. 136. Hansson L, Lindholm LH, Niskanen L et al. Principal results of the Captopril Prevention Project (CAPPP). Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet (in press)
137. 137. Curb JD, Pressel SL, Cutler JA et al. (1996) Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276: 1886-1892
138. 138. Malmberg K, Rydén L, Wedel H (1998) Calcium antagonists, appropriate therapy for diabetic patients with hypertension? Eur Heart J 19: 1269-1272
139. 139. Pyorälä K, Olsson AG, Pedersen TR et al. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20: 614-620
140. 140. Kylin E (1923) Studien über das Hypertonie-Hyperglykämie-Hyperurikaemie Syndrom. Zentralblatt für Innere Medizin 7: 105-112
141. 141. Himsworth HP (1939) Mechanisms of diabetes mellitus (Goulstonian Lecture). Lancet 2: 1-6, 65-68, 118-122, 171-175
142. 142. Vague J (1949) Le diabète de la femme androide. Presse Méd. Paris 57: 835-837
143. 143. Vague J (1952) Conditions étiologiques et évolution générale du diabète. Marseille Méd 89: 427-444
144. 144. Avogaro P, Creapaldi G (1965) Essential hypertension, hyperlipemia, obesity and diabetes. European Association for the Study of Diabetes. Diabetologia 1: 137 (Abstract)
145. 145. Jarrett RJ (1992) In defence of insulin: a critique of syndrome X. Lancet 340: 469-471
146. 146. Karlefors T (1966) Circulatory studies during exercise with particular reference to diabetes. Acta Med Scand 180 [Sup-pl 449]:1-87
147. 147. Christensen CK (1991) The pre-proteinuric phase of diabetic nephropathy. Dan Med Bull 38: 145-159
148. 148. Vittinghus E, Mogensen CE (1981) Albumin excretion and renal hemodynamic response to physical exercise in normal and diabetic man. Scand J Clin Lab Invest 41: 627-632
149. 149. Vittinghus E, Mogensen CE (1982) Graded exercise and protein excretion in diabetic man and the effect of insulin treatment. Kidney Int 21: 725-729
150. 150. Mogensen CE, Vittinghus E (1975) Urinary albumin excretion during exercise in juvenile diabetes. A provocative test for early abnormalities. Scand J Clin Lab Invest 35: 295-300
151. 151. Mogensen CE, Sølling K (1977) Studies on renal tubular protein reabsorption: Partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 37: 477-486
152. 152. Mogensen CE, Vittinghus E, Sølling K (1975) Increased urinary albumin, light chain, and beta-2-microglobulin excretion after intravenous arginine administration in normal man. Lancet II:581-583
153. 153. Mogensen CE, Christensen NJ, Gundersen HJG (1978) The acute effect of insulin on renal haemodynamics and protein excretion in diabetics. Diabetologia 15: 153-157
154. 154. Parving H-H, Christiansen JS, Noer I, Tronier B, Mogensen CE (1980) The effect of glucagon infusion on kidney function in short-term insulin-dependent juvenile diabetics. Diabetologia 19: 350-354
155. 155. Parving H-H, Noer I, Kehlet H, Mogensen CE. Svendsen PAa, Heding L (1977) The effect of short-term glucogen infusion on kidney function in normal man. Diabetologia 13: 323-325
156. 156. Parving H-H, Noer I, Mogensen CE, Svendsen PA (1978) Kidney function in normal man during short-term growth hormone infusion. Acta Endocrinol (Copenhagen) 89: 796-800
157. 157. Mogensen CE, Vittinghus E, Sølling K (1979) Abnormal albumin excretion after two provocative renal test in diabetes: Physical exercise and lysine injection. Kidney Int 16: 385-393
158. 158. Hinman AT, Engel BT, Bickford AF (1962) Portable blood pressure recorder. Accuracy and preliminary use in evalutating intradaily variations in pressure. Am Heart J 63: 663-668
159. 159. Richardson DW, Honour AJ, Fenton GW, Stott FH and Pickering GW (1964) Variation in arterial pressure throughout the day and night. Clin Sci 26: 445-460
160. 160. Rubler S, Abenavoli T, Greenblatt HA, Dixon JF, Cieslik CJ (1982) Ambulatory blood pressure monitoring in diabetic males: A method for detecting blood pressure elevations undisclosed by conventional methods. Clin Cardiol 5: 447-454
161. 161. Hansen KW, Christensen CK, Andersen PH, Mau Pedersen M, Christiansen JS, Mogensen CE (1992) Ambulatory blood pressure in microalbuminuric type 1 diabetic patients. Kidney Int 41: 847-854
162. 162. Hansen KW, Klein F, Christensen PD et al. (1994) Effects of captopril on ambulatory blood pressure, renal and cardiac function in microalbuminuric type 1 diabetic patients. Diabetes Metab 20: 485-493
163. 163. Hansen KW, Mau Pedersen M, Christensen CK, Christiansen JS, Mogensen CE (1992) Normoalbuminuria ensures no reduction of renal function in Type 1 (insulin-dependent) diabetic patients. J Intern Med 232: 161-167
164. 164. Hansen KW, Mau Pedersen M, Christiansen JS, Mogensen CE (1993) Acute renal effects of angiotensin converting enzyme inhibition in microalbuminuric type 1 diabetic patients. Acta Diabetol 30: 149-153
165. 165. Hansen KW, Mau Pedersen M, Christiansen JS, Mogensen CE (1993) Diurnal blood pressure variations in normoalbuminuric type 1 diabetic patients. J Intern Med 234: 175-180
166. 166. Hansen KW, Mau Pedersen M, Christiansen JS, Mogensen CE (1994) Night blood pressure and cigarette smoking; disparate association in healthy subjects and diabetic patients. Blood Pressure 3: 381-388
167. 167. Hansen KW, Mau Pedersen M, Marshall SM, Christiansen JS, Mogensen CE (1992) Circadian variation of blood pressure in patients with diabetic nephropathy. Diabetologia 35: 1074-1079
168. 168. Hansen KW, Poulsen PL, Christiansen JS, Mogensen CE (1995) Determinants of 24-h blood pressure in IDDM patients. Diabetes Care 18: 529-535
169. 169. Hansen KW, Poulsen PL, Mogensen CE (1994) Ambulatory blood pressure and abnormal albuminuria in type 1 diabetic patients. Kidney Int 45 [Suppl 45]:S134-S140
170. 170. Hansen KW, Sørensen K, Christensen PD, Pedersen EB, Christiansen JS, Mogensen CE (1995) Night blood pressure: Relation to organ lesions in microalbuminuric type 1 diabetic patients. Diabet Med 12: 42-45
171. 171. Poulsen PL, Hansen KW, Mogensen CE (1994) Ambulatory blood pressure in the transition from normo-to microalbuminuria. A longitudinal study in IDDM patients. Diabetes 43: 1248-1253
172. 172. Poulsen PL, Ebbehøj E, Hansen KW, Mogensen CE (1997) 24-h blood pressure and autonomic function is related to albumin excretion within the normoalbuminuric range in IDDM patients. Diabetologia 40: 718-725
173. 173. Poulsen PL, Bek T, Ebbehøj E, Hansen KW, Mogensen CE (1998) 24-h ambulatory blood pressure and retinopathy in normoalbuminuric IDDM patients. Diabetologia 41: 105-110
174. 174. Poulsen PL, Juhl B, Ebbehøj E, Klein F, Christiansen C, Mogensen CE (1997) Elevated ambulatory blood pressure in microalbuminuric IDDM patients is inversely associated with renal plasma flow. A compensatory mechanism? Diabetes Care 20: 429-432
175. 175. Hansen KW, Poulsen PL, Ebbehøj E (1998) Blood pressure elevation in diabetes: the results from 24-h ambulatory blood pressure recordings. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 335-356
176. 176. Pinkney JH, Denver AE, Yudkin JS (1997) Ambulatory blood pressure monitoring in diabetes: An analysis of its potential in clinical practice. Cardiovascular Risk Factors 7: 175-183
177. 177. Poulsen PL, Ebbehøj E, Mogensen CE (1998) Early ACE-intervention in microalbuminuria: 24 h BP, renal function, and exercise changes. Nephrol Dial Transplant 13: 1056-1079
178. 178. Poulsen PL, Ebbehøj E, Hansen KW, Mogensen CE (1998) Effects of smoking on 24-h ambulatory blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus patients. Am J Hypertens 11: 1093-1099
179. 179. Azar ST, Birbari A (1998) Nocturnal blood pressure elevation in patients with type 1 diabetes receiving intensive insulin therapy compared with that in patients receiving conventional insulin therapy. J Clin Endocrinol Metab 83: 3190-3192
180. 180. Wallenius G (1954) Renal clearance of dextran as a measure of glomerular permeability. Acta Soc Med Upsaliensis [Suppl 4]
181. 181. Lins H, Jahnke K, Scholtan W (1959) Über die Permeabilität makromolekularer Stoffe. In: Oberdisse K, Jahnke K (eds) Die Niere bei diabetischen und anderen Nephropathien in Diabetes Mellitus. Proceedings of the III. Congress of the International Diabetes Federation. Georg Thieme Verlag, Stuttgart, pp 203-206
182. 182. Lambert PP, Gassée JP, Askenasi R (1968) La perméabilité du rein aux macromolécules physiopathologie de la protéinurie. In: Lambert PP (ed) Acquisitions récentes de physiopathologie rénale. Editions Desoer S. A., Liège, Belgique, pp 181-214
183. 183. Deckert T, Kofoed-Enevoldsen A, Vidal P, Nørgaard K, Andreasen HB, Feldt-Rasmussen B (1993) Size- and charge selectivity of glomerular filtration in type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 36: 244-251
184. 184. Myers BD, Nelson RG, Williams GW et al. (1991) Glomerular function in Pima Indians with noninsulin-dependent diabetes mellitus of recent onset. J Clin Invest 88: 524-530
185. 185. Morelli E, Loon N, Meyer T, Peters W, Myers BD (1990) Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 39: 76-82
186. 186. Gaster B, Hirsch IB (1998) The effects of improved glycemic control on complications in type 2 diabetes. Archives of Internal Medicine 158: 134-140
187. 187. Krolewski AS, Laffel LMB, Krolewski M, Quinn M, Warram JH (1995) Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332: 1251-1255
188. 188. Microalbuminuria Collaborative Study Group, UK (1995) Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 311: 973-977
189. 189. Christensen CK, Mogensen CE (1985) The course of incipient diabetic nephropathy: Studies of albumin excretion and blood pressure. Diabetic Medicine 2: 97-102
190. 190. Christensen CK, Mogensen CE (1985) Effect of antihypertensive treatment on progression of disease in incipient diabetic nephropathy. Hypertension 7:II-109-II-113
191. 191. Christensen CK, Mogensen CE (1987) Antihypertensive treatment: long-term reversal of progression of albuminuria in incipient diabetic nephropathy. A longitudinal study of renal function. J Diabetes Complications 1: 45-52
192. 192. Mau Pedersen M, Christensen CK, Hansen KW, Christiansen JS, Mogensen CE (1991) ACE-inhibition and renoprotection in early diabetic nephropathy. Response to enalapril acutely and in long-term combination wtih conventional antihypertensive treatment. Clin Invest Med 14: 642-651
193. 193. Mau Pedersen M, Hansen KW, Schmitz A, Sørensen K, Christensen CK, Mogensen CE (1992) Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy. Kidney Int 41: 883-890
194. 194. Mogensen CE, Pedersen M.M, Ebbehøj E, Poulsen PL, Schmitz A (1997) Combination therapy in hypertension-associated diabetic renal disease. International Journal of Clinical Practice [Suppl] 90: 52-58
195. 195. Marre M, Chatellier G, Leblanc H, Guyenne T-T, Ménard J, Passa PH (1988) Prevention of diabetic nephropathy with Enalapril in normotensive diabetics with microalbuminuria. BMJ 297: 1092-1095
196. 196. Mathiesen ER, Hommel E, Giese J, Parving H-H (1991) Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetic patients with microalbuminuria. BMJ 303: 81-87
197. 197. Mathiesen ER, Hommel E, Hansen HP, Parving H-H (1998) Preservation of normal GFR in type 1 diabetic patients with microalbuminuria under long-term (8 years) ACE inhibition. Nephrol Dial Transplant 13: 1062
198. 198. Melbourne Diabetic Nephropathy Study Group (1991) Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 302: 210-216
199. 199. Barnes DJ, Cooper M, Gans DJ, Laffel L, Mogensen CE, Viberti GC (1996) Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in insulin-dependent diabetic patients with microalbuminuria. Diabetologia 39: 587-593
200. 200. Ravid M, Lang R, Rachmani R, Lishner M (1996) Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Archives of Internal Medicine 156: 286-289
201. 201. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R (1998) Use of enalapril to attenuate decline in renal function in normotensive patients with type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med 128: 982-988
202. 202. Viberti GC, Mogensen CE, Groop L, Pauls JF for the European Microalbuminuria Captopril Study Group (1994) Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271: 275-279
203. 203. Charturvedi N (1998) When should ACE inhibitors be used in IDDM patients? A combined analysis of clinical trials. Diabetologia 41:A5 (Abstract)
204. 204. Bennett PH, Haffner S, Kasiske BL et al. (1995) Screening and management of microalbuminuria in patients with diabetes mellitus - recommendations to the scientific advisory board of the national kidney foundation from an ad hoc committee of the council on diabetes mellitus of the national kidney foundation. Am J Kidney Dis 25: 107-112
205. 205. Mogensen CE (1971) Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes. Scand J Clin Lab Invest 28: 91-100
206. 206. Mogensen CE (1971) Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic man. Scand J Clin Lab Invest 28: 101-109
207. 207. Mogensen CE (1976) Progression of nephropathy in long-term diabetes with proteinuria and effect of initial hypertensive treatment. Scand J Clin Lab Invest 36: 383-388
208. 208. Mogensen CE (1976) High blood pressure as a factor in the progression of diabetic nephropathy. Acta Med Scand [Suppl 602]:29-32
209. 209. Mogensen CE, Hansen KW, Mau Pedersen M, Christensen CK (1991) Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 14[Suppl 4]:13-26
210. 210. Mogensen CE (1997) How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 46 [Suppl 2]S104-S111
211. 211. Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285: 685-688
212. 212. Parving H-H, Smidt UM, Andersen AR, Svendsen PAA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet I:1175-1179
213. 213. Parving H-H, Andersen AR, Schmidt UM, Hommel E, Mathiesen ER, Svendsen PAA (1987) Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 294: 1443-1447
214. 214. Parving H-H, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P (1996) Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 49: 1778-1782
215. 215. Parving H-H, Hommel E (1989) Prognosis in diabetic nephropathy. BMJ 299: 230-233
216. 216. Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T (1989) Improved survival in patients with diabetic nephropathy. Diabetologia 32: 884-886
217. 217. Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M (1992) Renal protective effect of enalapril in diabetic nephropathy. BMJ 304: 339-343
218. 218. Lewis E, Hunsicker L, Bain R, Rhode R (1993) The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462
219. 219. Weir MR, Dworkin LD (1998) Antihypertensive drugs, dietary salt, and renal protection: How low should you go and with which therapy? Am J Kidney Dis 32(1):1-22
220. 220. de Courten M, Böhlen L, Weidmann P (1994) Antihypertensive treatment of diabetic and nondiabetic renal disease: drug-specific differences in reducing proteinuria. J Hypertens 12 [Suppl 3]:S112
221. 221. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G on behalf of the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352: 1252-1256
222. 222. Nyberg G, Blohmé G, Nordén G (1987) Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 30: 82-86
223. 223. Pickup JC, Keen H, Parsons JA, Alberti KGMM (1978) Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1: 204-207
224. 224. Christensen CK, Christiansen JS, Christensen T, Hermansen K, Mogensen CE (1986) The effect of six months continuous subcutaneous insulin infusion on kidney function and size in insulin-dependent diabetics. Diabetic Medicine 3: 29-32
225. 225. Møller A, Rasmussen L, Ledet T, Christiansen JS, Christensen CK, Mogensen CE, Hermansen K (1986) Lipoprotein changes during CSII treatment in IDDM patients Scand J Clin Lab Invest 46: 471-475
226. 226. Thuesen L, Christiansen JS, Sørensen KE et al. (1986) Exercise capacity and cardiac function in type 1 diabetic patients treated with continuous subcutaneous insulin infusion. A controlled study. Scand J Clin Lab Invest 46: 779-784
227. 227. Hermansen K, Møller A, Christensen CK et al. (1987) Diurnal plasma profiles of metabolite and hormone concentration in insulin-dependent diabetic patients during conventional insulin treatment and continuous subcutaneous insulin infusion. A controlled study. Acta Endocrinol (Copenhagen) 114: 433-439
228. 228. Mogensen CE (1988) Therapeutic inverventions in nephropathy of IDDM. Diabetes Care 11 [Suppl 1]:10-15
229. 229. Jakobsen J, Christiansen JS, Christensen CK, Hermansen K, Schmitz A, Mogensen CE (1988) Autonomic and somatosensory nerve function after two years of continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes 37: 452-455
230. 230. Hermansen K, Schmitz O, Boye N, Christensen CK, Christiansen JS, Alberti KGMM, Ørskov H, Mogensen CE (1988) Glucagon responses to intravenous arginine and oral glucose in insulin-dependent diabetic patients during six months conventional or continous subcutaneous insulin infusion. Metabolism 37: 640-644
231. 231. Schmitz A, Christiansen JS, Christensen CK, Hermansen K, Mogensen CE (1989) Effect of pump versus pen treatment on glycemic control and kidney-function in long-term uncomplicated insulin-dependent diabetes-mellitus (IDDM). Dan Med Bull 36: 176-178
232. 232. Mogensen CE, Hansen KW (1990) Preventing or postponing renal disease in insulin-dependent diabetes by glycemic and nonglycemic intervention. In: Klinkmann H, Smeby LC (eds) Terminal Renal Failure: Therapeutic Problems, Possibilities, and Potentials. Contrib Nephrol, Karger, Basel 78: 73-101
233. 233. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC (1967) Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 61: 827
234. 234. Dubernard JM, Traeger J, Neyra P, Touraine JL, Tranchant D, Blanc-Brunat N (1978) A new method of preparation of segmental pancreatic grafts for transplantation. Trials in dogs and in man. Surgery 84: 633
235. 235. Sutherland DER, Dunn DL, Goetz FC et al. (1989) A 10-year experience with 290 pancreas transplants at a single institution. Ann Surg 210: 274-285
236. 236. Manske CL (1999) Risks and benefits of kidney and pancreas transplantation for diabetic patients. Diabetes Care (in press)
237. 237. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer M (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75
238. 238. Nyberg G, Holdaas H, Brekke IB, Hartmann A, Nordén G, Olausson M, Østerby R (1996) Glomerular ultrastructure in kidneys transplanted simultaneously with a segmental pancreas to patients with type 1 diabetes. Nephrol Dial Transplant 11: 1029-1033
239. 239. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM (1986) Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930
240. 240. Williams B, Cooper ME, McNally PG (1998) Antihypertensive treatment in NIDDM with special reference to abnormal albuminuria. Addendum regarding renovascular hypertension and renal artery stenosis (especially NIDDM). In: Mogensen CE (ed) The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publ, Boston, Dordrecht, London, pp 432-434
241. 241. Mogensen CE (1992) Angiotensin converting enzyme inhibitors and diabetic nephropathy. Their effects on proteinuria may be independent of their effects on blood pressure. Editorial. BMJ 304: 327-328
242. 242. Thuesen L, Christiansen JS, Falstie-Jensen N, Christensen CK, Hermansen K, Mogensen CE, Henningsen P (1985) Increased myocardial contractility in short-term Type 1 diabetic patients: an echocardiographic study. Diabetologia 28: 822-826
243. 243. Parving H-H, Viberti GC, Keen H, Christiansen JS, Lassen NA (1983) Haemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 32: 943-949
244. 244. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H (1995) Albuminuria and poor glycemic control predicts mortality in NIDDM. Diabetes 44: 1303-1309
245. 245. Stanton A (1998) Calcium channel blockers. BMJ 316: 471-473
246. 246. Mogensen CE (1998) Drug treatment for hypertensive patients in special situations: Diabetes and hypertension. Clin Exp Hypertens (in press)
247. 247. Nielsen S, Dollerup J, Nielsen B, Jensen HA, Mogensen CE (1997) Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 12: 19-23
248. 248. Nielsen S (1998) Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes. Diabetologia 41[Suppl 1]:A5 (Abstract)
249. 249. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR (1985) The changing natural history of nephropathy in type I diabetes. Am J Med 78: 785-794
250. 250. (1948) The controlled therapeutic trial [editorial] BMJ 2: 791-792
251. 251. Chalmers I (1998) Unbiased, relevant and reliable assessments in health care. BMJ 317: 1167-1168
252. 252. University Group Diabetes Program (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 19 [Suppl 2]: 747-830
253. 253. Creutzfeldt W (1994) The discovery of the oral treatment of diabetes mellitus with sulphonylureas. In: Mogensen CE, Standl E (eds) Research methodologies in Human Diabetes, part 1. Walter de Gruyter, Berlin, New York, pp 11-20
254. 254. Peto R, Collins R, Gray R (1995) Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 48(1): 23-40
255. 255. Thompson SG, Pocock SJ (1991) Can meta-analyses be trusted? Lancet 338: 1127-30
256. 256. Thomson SG (1994) Why sources of heterogeneity in meta-analysis should be investigated. BMJ 309: 1351-1355
257. 257. Feinstein AR (1995) Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 48: 71-79
258. 258. Spitzer WO (1995) The challenge of meta-analysis (Editor's Keynote Address). J Clin Epidemiol 48: 1-4
259. 259. Victor N (1995) The challenge of meta-analysis: Discussion. Indications and contra-indications for meta-analysis. J Clin Epidemiol 48: 5-8
260. 260. Sharp SJ, Thomson SG, Altman DG (1996) The relation between treatment benefit and underlying risk in meta-analysis. BMJ 313: 1550-1551
261. 261. Lelorier J, Geneviève G, Benhaddad A, Lapierre J, Derderian F (1997) Discrepancies between meta-analyses and subsequent large randomized controlled trials. New Engl J Med 337: 536-542
262. 262. WHO-ISH (1975) Effectiveness of treatment of mild hypertension. WHO Geneva CVD/75.5
263. 263. 1999 Guidelines for the management of hypertension: Memorandum from a World Health Organization/International Society of Hypertension Meeting (1998) J Hypertens (in press)
264. 264. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (1997) Arch Intern Med 157: 2413-2446
265. 265. Recommendations et références médicales de l'annees. Diagnostic et traitement de l'hypertension artérielle essentielle de l'adulte de 20 à 80 ans (1998) Journal des Maladies Vasculaires (Paris) 23, 3: 204-231
266. 266. British Hypertension Society Guidelines (1999) (in press)
267. 267. American Diabetes Association (1998) Standards of medical care for patients with diabetes mellitus. Diabetes Care 21:S23-S31
268. 268. American Diabetes Association (1998) Diabetic nephropathy. Diabetes Care 21:S50-S53
269. 269. National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease (1996) 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med 156: 1938-1947
270. 270. Lundbæk K (1953) Long-term diabetes. The clinical picture in diabetes mellitus of 15-25 years' duration with a follow-up of a regional series of cases. Munksgaard, Copenhagen and Lange, Maxwell & Springer Ltd., London, New York
271. 271. Cooper ME (1998) Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 352: 213-219
272. 272. Parving H-H (1998) Is antihypertensive treatment the same for NIDDM and IDDM patients? Diabetes Research and Clinical Practice 39 [Suppl]:S43-S47
273. 273. Anitschkow N, Chalatow S (1913) Uber experim. Cholesterinstesotose, Zentralbl. f. alg Pathol u. pathol Anst Bd 24: 379-403
274. 274. Walker JD (1998) Non-glycaemic intervention in diabetic nephropathy: The role of dietary protein intake. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus. Kluwer Academic Publications, Boston, Dordrecht, London, pp 443-453
275. 275. Feldt-Rasmussen B, Hegedüs L, Mathiesen ER, Deckert T (1991). Kidney volume in type 1 (insulin-dependent) diabetic patients with normal or increased urinary albumin excretion: effect of long-term improved metabolic control. Scand J Clin Lab Invest, 51: 31-36
276. 276. Cambier P (1934) Application de la théorie de Rehberg a l'etude clinique des affections rénales et du diabete. Annales Médicine 35: 273-299
277. 277. Fiaschi E, Grassi B, Andres G (1952). La funzione renal nel diabete mellito. Rassegna di Fisiopatologia Clinica & Terapeutica 24: 373-410
278. 278. Stadler G, Schmid R, Wolff MV (1960) Funktionelle Mikroangiopathie der Nieren beim behandelten Diabetes mellitus im Kindesalter. Dtsch Med Wochenschr 85: 346
279. 279. Ditzel J, Schwartz M (1967) Abnormally increased glomerular filtration rate in short-term insulin-treated diabetic subjects. Diabetes 16: 264
280. 280. Mogensen CE (1972) Glomerular filtration rate and renal plasma flow in long-term juvenile diabetics without proteinuria. BMJ 4: 257-259
281. 281. Yip WJ, Jones LS, Wiseman JM, Hill C, Viberti GC (1996) Glomerular hyperfiltration in the prediction of nephropathy in IDDM. Diabetes 45: 1729-1733
282. 282. Keen H, Chlouverakis C (1963) An immunoassay method for urinary albumin at low concentrations. Lancet ii: 913
283. 283. Miles DW, Mogensen CE, Gundersen HJG (1970) Radioimmunoassay for urinary albumin using a single antibody. Scand J Clin Lab Invest 26: 5-11
284. 284. Mogensen CE (1971) Urinary albumin excretion in early and long-term juvenile diabetes. Scand J Clin Lab Invest 28: 183-193
285. 285. Mogensen CE (1995) Management of early nephropathy in diabetic patients. Ann Rev Med 46: 79-93
286. 286. Mogensen CE (1988) Management of diabetic renal involvement and disease. Lancet I:867-870
287. 287. Mogensen CE, Keane WF, Bennett PH et al. (1995) Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346: 1080-1084
288. 288. Keen H, Chlouverakis C (1964) Urinary albumin excretion and diabetes mellitus. Lancet ii:1155
289. 289. Mogensen CE, Vestbo E, Poulsen PL et al. (1995) Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 18: 572-581
290. 290. Mogensen CE, Poulsen PL (1994) Epidemiology of microalbuminuria in diabetes and in the background population. Curr Opin Nephrol Hypertens 3: 248-256
291. 291. Borch-Johnsen K, Wenzel H Viberti GC, Mogensen CE (1993) Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 306: 1722-1725
292. 292. Kimmelstiel P, Wilson C (1936) Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 12: 83-95
293. 293. Kimmelstiel P (1959) On Diabetic Glomerulosclerosis. Diabetes Mellitus. Proceedings of the III Kongress of the International Diabetes Federation. Georg Thieme Verlag, Stuttgart, pp 178-184
294. 294. Gellman DD, Pirani C, Soothill JF, Muehrcke RC, Kark RM (1959) Diabetic nephropathy: a clinical and pathological study based on renal biopsies. Medicine 38: 321
295. 295. Olsen S (1998) Light microscopy of diabetic glomerulopathy: the classic lesion. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus. 217-226. 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 217-226
296. 296. Olsen S, Mogensen CE (1996) How often is Type II diabetes mellitus complicated with non-diabetic renal disease? A material of renal biopsies and an analysis of the literature. Diabetologia 39: 1638-1645
297. 297. Thomsen CAA (1965) The Kidney in Diabetes Mellitus. A Clinical and Histological Investigation Based on Renal Biopsy Material. Munksgaard, Copenhagen
298. 298. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC (1984) Structural functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155
299. 299. Reaven GM (1997) The kidney: An unwilling accomplice in Syndrome X. Am J Kidney Dis 30: 928-931
300. 300. Keiding NR, Root HF, Marble A (1952) Importance of control of diabetes in prevention of vascular complications. JAMA 150: 964-969
301. 301. Wang PH, Lau J, Chalmers TC (1993) Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 341: 1306-1309
302. 302. Mulec H, Blohmé G, Grände B, Björck S (1998) The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 13: 651-655
303. 303. Chaturvedi N, Sjolie A-K, Stephenson JM et al. and the EUCLID Study Group (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351: 28-31
304. 304. Crepaldi G, Carta Q, Deferrari G et al. and The Italian Microalbuminuria Study Group in IDDM (1998) Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 21: 104-110
305. 305. Cooper M, McNally P (1998) Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 419-434
306. 306. Gæde P, Vedel P, Parving H-H, Pedersen O (1998) The Steno Type 2 study: Intensive multifactorial intervention delays the progression of micro-and macroangiopathy in microalbuminuric Type 2 diabetic patients. Diabetologia 41(1): (Abstract 7)
307. 307. Anderson S (1998) Pathogenesis of diabetic glomerulopathy: The role of glomerular hemodynamic factors. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 297-306
308. 308. Mau Pedersen M, Schmitz A, Pedersen EB, Danielsen H, Christiansen JS (1988) Acute and long-term renal effects of angiotensin converting enzyme inhibition in normotensive, normoalbuminuric insulin-dependent diabetic patients. Diabetic Med 5: 562-569
309. 309. Viberti GC, Keen H, Wiseman MJ (1987) Raised arterial pressure in parents of proteinuric insulin-dependent diabetics. BMJ 295: 515-517
310. 310. Doria A, Warram JH, Krolewski AS (1995) Genetic susceptibility to nephropathy in insulin-dependent diabetes: from epidemiology to molecular genetics. Diabetes Metab Rev 11: 287-314
311. 311. Marre M, Bouhanick B (1997) Genetics and diabetic nephropathy. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 399-408
312. 312. Mogensen CE (1998) Exercise and the kidney in diabetes. In: The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 191-198
313. 313. Mogensen CE, Schmitz A, Christensen CK (1988) Comparative Renal Pathophysiology Relevant to IDDM and NTDDM Patients. Diabetes 4(5):453-483
314. 314. Tuominen JA, Ebeling P, Koivisto VA (1998) Long-term lisinopril therapy reduces exercise-induced albuminuria in normoalbuminuric normotensive IDDM patients. Diabetes Care 21: 1345-1348
315. 315. Flyvbjerg A, Hill C, Nielsen B, Grønbæk H, Bak M, Christiansen T, Logan A, Ørskov H (1998) The role of growth hormone, insulin-like growth factors, epidermal growth factor and transforming growth factor-β in diabetic kidney disease, an update. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 307-320
316. 316. Ziyadeh FN, Cheol Han, Mogyorosi A (1998) Transforming growth factor beta and other cytokines in experimental and human diabetic nephropathy. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 321-334
317. 317. Koya D, King GL (1998) Protein kinase C in diabetic renal involvement, the perspective of inhibition. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 263-268
318. 318. Hollenberg N (1998) ACE-inhibition and angiotensin II receptor blockade, and diabetic nephropathy. In: Mogensen CE (ed) The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordecht, London, pp 393-398
319. 319. Cooper M, Jerums G (1998) Advanced glycation end-products and diabetic renal disease. In: Mogensen CE, The Kidney and hypertension in diabetes mellitus, 4th ed., Kluwer Academic Publ., Boston, Dordrecht, London, pp 257-262
320. 320. Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer M (1989) Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 320: 966-970
321. 321. Fioretto P, Steffes MW, Mauer M (1994) Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 43: 1358-1364